Skip to main content

Press Releases

May 16, 2023

Washington, D.C. (May 16, 2023)—Below is Ranking Member Jamie Raskin's opening statement, as prepared for delivery, at today's Committee on Oversight and Accountability hearing entitled "Overdue Oversight of the Capital City: Part II."

Issues: DC

May 11, 2023

Washington, D.C. (May 11, 2023)—Rep. Jamie Raskin, Ranking Member of the Committee on Oversight and Accountability, led Committee Democrats in defending the free market principles behind responsible investing that protect the savings and retirements of Americans and promote prudent planning for long-term challenges, such as those associated with climate change.


May 10, 2023

Washington, D.C. (May 10, 2023)—Below is Ranking Member Gerald E.


May 10, 2023

Washington, D.C. (May 10, 2023)—Today, Rep. Jamie Raskin, Ranking Member of the Committee on Oversight and Accountability, issued the following statement after Committee Republicans released cherry-picked bank records and mischaracterized information about Suspicious Activity Reports (SARs) to distract from their failure to find any evidence of wrongdoing by President Biden:


May 10, 2023

Washington, D.C. (May 10, 2023)—Below is Ranking Member Jamie Raskin's opening statement, as prepared for delivery, at today's hearing on "ESG Part I: An Examination of Environmental, Social, and Governance Practices with Attorneys General."


May 9, 2023

Washington, D.C. (May 9, 2023)—Today, Committee on Oversight and Accountability Ranking Member Jamie Raskin, and Committee on Homeland Security Ranking Member Bennie G. Thompson, issued the following statement after the Committees' voluntary transcribed interview with U.S. Border Patrol agent Aaron Heitke, Chief Patrol Agent of the San Diego Sector:


May 9, 2023

WASHINGTON—The U.S. Government Accountability Office released a new report today that found the amount of taxpayer contributions to pharmaceutical research and development has frequently been underreported in patent filings, while pharmaceutical companies continue to cite R&D expenditures as justification for raising drug prices.